CTIS2023-509059-15-00招募中1 期
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors - GCT1046-01
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Genmab A/S
- 入组人数
- 427
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •For Dose Escalation: • Measurable disease; • Adequate hematologic, coagulation, hepatic and renal function as defined per protocol; • Subjects must have a histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy;, For Dose Expansion: • Measurable disease • Adequate hematologic, coagulation, hepatic and renal function as defined per protocol; • Subjects must have histologically or cytological confirmed diagnosis of relapsed or refractory, advanced and/or metastatic NSCLC, EC, UC, TNBC, SCCHN, or cervical cancer who are no longer candidates for or refuse standard therapy (if subjects had access and were eligible for the respective treatments); For detailed inclusion criteria (with specific criteria for expansion cohorts) please refer to the Clinical Trial Protocol.
排除标准
- •Subject has uncontrolled intercurrent illness, including but not limited to: • Ongoing or active infection requiring intravenous treatment with antiinfective therapy that has been administered <2 weeks prior to first dose; • Symptomatic congestive heart failure; • Uncontrolled hypertension defined as systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg; • Ongoing or recent (within 1 year) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs); • Subjects with a history of grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment should be excluded; • Subjects with a prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade are excluded; • History of chronic liver disease or evidence of hepatic cirrhosis; • History of non-infectious pneumonitis; • History of organ allograft; • Serious, non-healing wound, skin ulcer, or bone fracture; • All subjects should undergo a computed tomography (CT) scan or magnetic resonance imaging (MRI) of the brain to document new or existing CNS lesions. For detailed exclusion criteria (with specific criteria for expansion cohorts) please refer to the Clinical Trial Protocol., • Prior therapy: • Radiotherapy within 14 days prior to first GEN1046 administration or received lung radiation therapy of >30 Gy within 6 months of the first dose of trial treatment; • Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1046 administration; • Subjects who discontinued treatment due to disease progression within the first 6 weeks of a CPI containing treatment; • Prior treatment with a 4-1BB (CD137) targeted agent; • Prior treatment with a T-cell agonist or anti-CTLA-4 targeted agent within 12 weeks prior to the initiation of treatment; • Toxicities from previous anti-cancer therapies; For detailed exclusion criteria (with specific criteria for expansion cohorts) please refer to the Clinical Trial Protocol.
研究者
相似试验
进行中（未招募）
1 期
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumorsMalignant solid tumors: Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastric (incl. esophagogastric junction) cancer, pancreatic cancer or urothelial cancer.MedDRA version: 20.1 Level: LLT Classification code 10065143 Term: Malignant solid tumour System Organ Class: 100000004864EUCTR2017-001394-16-ESGenmab B.V.206
进行中（未招募）
1 期
A Safety study of GEN1047 in patients with malignant solid tumorsMalignant Solid Tumors, per protocol GCT1047-01MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2021-001790-23-ESGenmab A/S380
进行中（未招募）
1 期
A Safety study of GEN1044 in patients with malignant solid tumors.EUCTR2019-003998-26-ESGenmab A/S378
招募中
1 期
GEN1047 for Solid Tumors - First in Human (FIH) TrialMalignant Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2024-510722-10-00Genmab A/S333
进行中（未招募）
1 期
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumorsMalignant solid tumors:Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastric (incl. esophagogastric junction) cancer, pancreatic cancer or urothelial cancer.MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864EUCTR2017-001394-16-GBGenmab B.V.48